Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2005
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239131 Interactive system for presenting and eliminating substances
10/27/2005US20050238694 Satiety inducing composition
10/27/2005US20050236328 Chitosan-containing polysaccharide, method for preparing the same and use thereof
10/27/2005DE102004017739A1 New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis
10/27/2005CA2563689A1 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005CA2563104A1 Association between a heterocyclic compound and an antioxidant agent and pharmaceutical compositions containing them
10/27/2005CA2562885A1 Follistatin variant polypeptide
10/27/2005CA2562529A1 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
10/27/2005CA2562391A1 Solid pharmaceutical preparation
10/27/2005CA2562369A1 Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
10/27/2005CA2561877A1 Use of mic-1 or modulating agent thereof to modulate appetite or body weight
10/27/2005CA2559698A1 Novel alkyne compounds exhibiting an mch antagonistic effect and drugs containing said compounds
10/26/2005EP1589115A2 Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
10/26/2005EP1589023A1 Oligosaccharide derivative
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1589009A1 Vitamin d3 lactone derivative
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1588709A1 Vitamin comprising pyroloquinoline quinone and use thereof
10/26/2005EP1588708A1 Process for producing coated preparation
10/26/2005EP1588703A1 Fatigue reducing agent
10/26/2005EP1588629A1 Matrix-forming composition containing pectin
10/26/2005EP1587827A1 Obesity-related genes
10/26/2005EP1587499A1 Nanoparticulate topiramate formulations
10/26/2005EP1587479A2 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
10/26/2005EP1430056B1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
10/26/2005EP1423109B1 Compositions comprising pectin and ascorbic acid
10/26/2005EP1381607B1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/26/2005EP1289965B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/26/2005EP1246626B1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance
10/26/2005EP1212081B1 Use of ace inhibitors in the prevention of congestive heart failure
10/26/2005EP1185277B1 Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer
10/26/2005EP1183229B1 Glucagon antagonists/inverse agonists
10/26/2005EP1140148B1 Shelf-stable solution formulation of glucagon-like peptide-1
10/26/2005EP1082107B1 Controlled release lipoic acid
10/26/2005EP0975357B1 Transdermal delivery system
10/26/2005CN1688885A Assay for beta cell toxic macrolides
10/26/2005CN1688603A Treatment and prophylaxis with 4-1BB-binding agents
10/26/2005CN1688599A Use of dipeptidyl peptidase IV inhibitor
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688574A Indole-3-carboxamides as glucokinase(GK) activators
10/26/2005CN1688573A Pyrrole based inhibitors of glycogen synthase kinase 3
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688555A Novel bicyclic inhibitors of hormone sensitive lipase
10/26/2005CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688540A Novel vinyl carboxylic acid derivatives and their therapeutical use
10/26/2005CN1688534A Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising the
10/26/2005CN1688532A Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
10/26/2005CN1688341A Medicinal composition for lowering blood lipid level
10/26/2005CN1688325A Black soybean polysaccharides
10/26/2005CN1688302A Use of hydroxyoleic acid and similar compounds in the production of medicaments
10/26/2005CN1224624C 1, 8-naphthyridin-2 (1H)-one derivatives
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224420C Agent for treating visual cell function disorder
10/26/2005CN1224407C Medicine composition for treating diabetes, and its prepn. method
10/26/2005CN1224404C Onion extract with controlling action for angiocardiopathy
10/26/2005CN1224383C Blood sugar reducing compound
10/25/2005US6958357 Central nervous system disorders; antiallergens; respiratory system disorders
10/25/2005US6958355 Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
10/25/2005US6958352 Compounds for inhibiting insulin secretion and methods related thereto
10/25/2005US6958350 Chemical compounds
10/25/2005US6958347 Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
10/25/2005US6958346 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958332 Treating an interleukin-12 overproduction-related disorder; treating rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/20/2005WO2005097764A1 Thiazole derivative
10/20/2005WO2005097738A1 Novel sulfonamide derivative
10/20/2005WO2005097171A1 Antiobesity drug
10/20/2005WO2005097152A1 Turmeric extract-containing composition having improved caking capacity
10/20/2005WO2005097151A1 Antioxidant composition and products containing the same
10/20/2005WO2005097117A1 Thiadiazolidinones as gsk-3 inhibitors
10/20/2005WO2005097097A1 Agent for controlling cholesterol homeostasis-associated gene transcription activity mediated by fxr activation
10/20/2005WO2004113292A3 Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234223 Drug candidate compounds such as H3 receptor inverse agonists can be screened more easily and efficiently
10/20/2005US20050234129 Salts of nateglinide
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234056 Imidazoquinoline derivatives as adenosine A3 receptor ligands
10/20/2005US20050234051 5-Substituted 2-aryl-4 pyrimidinones
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234025 Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
10/20/2005US20050234022 Use of 2-alkoxyphenyl-substituted imidazotriazinones
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234008 Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
10/20/2005US20050234001 Methods and compositions for modulating gluconeogenesis using PGC-1
1 ... 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 ... 1298